Literature DB >> 3977850

Relations between high-affinity binding sites of markers for binding regions on human serum albumin.

U Kragh-Hansen.   

Abstract

Binding of warfarin, digitoxin, diazepam, salicylate and Phenol Red, individually or in different pair combinations, to defatted human serum albumin at ligand/protein molar ratios less than 1:1 was studied at pH 7.0. The binding was determined by ultrafiltration. Some of the experiments were repeated with the use of equilibrium dialysis in order to strengthen the results. Irrespective of the method used, all ligands bind to one high-affinity binding site with an association constant in the range 10(4)-10(6) M-1. High-affinity binding of the following pair of ligands took place independently: warfarin-Phenol Red, warfarin-diazepam, warfarin-digitoxin and digitoxin-diazepam. Simultaneous binding of warfarin and salicylate led to a mutual decrease in binding of one another, as did simultaneous binding of digitoxin and Phenol Red. Both effects could be accounted for by a coupling constant. The coupling constant is the factor by which the primary association constants are affected; in these examples of anti-co-operativity the factor has a value between 0 and 1. In the first example it was calculated to be 0.8 and in the latter 0.5. Finally, digitoxin and salicylate were found to compete for a common high-affinity binding site. The present findings support the proposal of four separate primary binding sites for warfarin, digitoxin (and salicylate), diazepam and Phenol Red. An attempt to correlate this partial binding model for serum albumin with other models in the literature is made.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3977850      PMCID: PMC1144637          DOI: 10.1042/bj2250629

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  21 in total

1.  The characterization of two specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1975-11       Impact factor: 4.436

2.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

3.  Binding of digitoxin to human serum proteins: influence of pH on the binding of digitoxin to human albumin.

Authors:  A Brock
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-01

4.  Independent binding of ligands to human serum albumin.

Authors:  R Brodersen; T Sjödin; I Sjöholm
Journal:  J Biol Chem       Date:  1977-07-25       Impact factor: 5.157

5.  Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters.

Authors:  J P Tillement; R Zini; P d' Athis; G Vassent
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

6.  A spectrophotometric micromethod for the determination of binding of phenol red to plasma proteins of various species.

Authors:  U Kragh-Hansen; J V Moller; M I Sheikh
Journal:  Pflugers Arch       Date:  1972       Impact factor: 3.657

7.  Effect of fatty acids on the binding of 1-anilino-8-naphthalenesulfonate to bovine serum albumin.

Authors:  E C Santos; A A Spector
Journal:  Biochemistry       Date:  1972-06-06       Impact factor: 3.162

8.  Removal of fatty acids from serum albumin by charcoal treatment.

Authors:  R F Chen
Journal:  J Biol Chem       Date:  1967-01-25       Impact factor: 5.157

Review 9.  Serum albumin: recent progress in the understanding of its structure and biosynthesis.

Authors:  T Peters
Journal:  Clin Chem       Date:  1977-01       Impact factor: 8.327

10.  Structural requirements for drug binding to site II on human serum albumin.

Authors:  S Wanwimolruk; D J Birkett; P M Brooks
Journal:  Mol Pharmacol       Date:  1983-11       Impact factor: 4.436

View more
  19 in total

1.  Estrogen mitogenic action. III. is phenol red a "red herring"?

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

2.  Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants.

Authors:  H Watanabe; U Kragh-Hansen; S Tanase; K Nakajou; M Mitarai; Y Iwao; T Maruyama; M Otagiri
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  Investigation of the Interaction Between Human Serum Albumin and Two Drugs as Binary and Ternary Systems.

Authors:  Nooshin Abdollahpour; Vahid Soheili; Mohammad Reza Saberi; Jamshidkhan Chamani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

4.  Fluorescent study of human blood plasma albumin alterations induced by ionizing radiation.

Authors:  Elena M Kirilova; Inta Kalnina; Tija Zvagule; Natalija Gabruseva; Natalja Kurjane; Irina I Solomenikova
Journal:  J Fluoresc       Date:  2010-02-24       Impact factor: 2.217

5.  Participation of the lone tryptophan residue of rat alpha-foetoprotein in its drug-binding sites. Comparison with rat serum albumin.

Authors:  F Hervé; M T Martin; K Rajkowski; P Dessen; N Cittanova
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

Review 6.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

7.  Five recombinant fragments of human serum albumin-tools for the characterization of the warfarin binding site.

Authors:  M Dockal; M Chang; D C Carter; F Rüker
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

8.  Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin.

Authors:  T Sakai; K Yamasaki; T Sako; U Kragh-Hansen; A Suenaga; M Otagiri
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

9.  Resonance energy transfer between tryptophan-214 in human serum albumin and acrylodan, prodan, and promen.

Authors:  José González-Jiménez; Manuel Cortijo
Journal:  Protein J       Date:  2004-07       Impact factor: 2.371

10.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.